| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 514110000 | Phosphorus is part of a ring | 25 |
| 20090209494 | 21-DEOXYMACBECIN ANALOGUES USEFUL AS ANTITUMOR AGENTS - The present invention relates to 21-deoxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and or prophylaxis of cancer or B-cell malignancies. | 08-20-2009 |
| 20090312290 | COMBINATION OF A NITROGEN MUSTARD ANALOGUE AND IMATINIB FOR TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA - The invention relates to a combination which comprises (a) a nitrogen mustard analogue selected from chlorambucil, chlornaphazine, estramustine, mechlorethamine, mechlorethamine oxide hydrochloride, novembichin, phenesterine, prednimustine, trofosfamide or uracil mustard and (b) 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide of formula | 12-17-2009 |
| 20090318391 | ANTI-CANCER THERAPY COMPRISING AN H2-BLOCKER, AT LEAST ONE ANTIINFLAMMATORY AGENT AND A CYTOTOXIC AGENT - The present invention relates to the treatment of a mammal with a pharmaceutical composition comprising an H2-blocker, at least one anti-inflammatory agent, a cytotoxic agent and, optionally, levamisole, a retinoid, an NFkB inhibitor, a redox quinone, an agent that enhances the intracellular accumulation of NADH+H+, a poly-alcohol, an inhibitor of pro-angiogenic growth factor(s) and an MMP inhibitor, such pharmaceutical composition allowing for the enhanced therapy and/or prevention of neoplastic diseases and disorders. | 12-24-2009 |
| 20100004210 | METHOD AND SUBSTANCES FOR TREATING T-CELL MEDIATED AUTOIMMUNE DISEASES - The invention relates to methods for treating T cell mediated autoimmune diseases, such as psoriasis and multiple sclerosis, in a human in need thereof, wherein a therapeutically effective amount of a substance which lowers the cellular glutathione content is administered to the human. | 01-07-2010 |
| 20100048513 | Novel inhibitors of chymase - The present invention is directed to a compound of formula (I), | 02-25-2010 |
| 20100234325 | 4-Peroxycyclophosphamide use thereof - 4-Peroxycyclophosphamide is provided along with its method of preparation. The compound is useful for treating human cancer, particularly human primary and metastatic malignant brain tumors. | 09-16-2010 |
| 20110082115 | Methods for Providing a System of Care for an Oxazaphosphorine Drug Regimen - The present invention provides methods of treating subjects with an oxazaphosphorines, methods of identifying subjects that are suitable for oxazaphosphorine treatment, and systems for ensuring the safety and efficacy of a treatment that includes oxazaphosphorine administration. | 04-07-2011 |
| 20110112055 | COMPOSITIONS AND METHODS FOR TREATING COLITIS - Disclosed herein are compositions and methods for treating colitis and other inflammatory bowel diseases, inter alia, indeterminate colitis, Crohn's disease, irritable bowel syndrome and ischemic colitis. | 05-12-2011 |
| 20110319365 | COMPLEXES OF 4-HYDROPEROXY IFOSFAMIDE AS ANTI-TUMOR AGENTS - The present disclosure concerns complexes of 4-hydroperoxy ifosfamide. In one embodiment the complexes can be represented by the formula | 12-29-2011 |
| 20120322768 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING PROTOZOAN INFECTIONS - Provided are compounds, compositions and methods for treating protozoan infections. | 12-20-2012 |
| 20130172296 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES - The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject. | 07-04-2013 |
| 20130261088 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION - The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer. | 10-03-2013 |
| 20140243294 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES - The present invention provides a method of hydroxylating or oxidizing a compound of interest in a subject (e.g., a cytotoxic oxazaphosphorine prodrug), by administering the compound of interest to the subject; and concurrently administering the subject a metalloporphyrin in an amount effective to hydroxylate or oxidize the compound of interest in the subject. | 08-28-2014 |
| 20140309194 | THERAPEUTIC AGENT FOR ARTHROSIS - This invention provides a therapeutic agent for arthrosis exerting inhibitory effects on articular cartilage destruction and high therapeutic effects on arthrosis. The invention provides a therapeutic agent for arthrosis which comprises, as an active ingredient, cyclic phosphatidic acid or carbacyclic phosphatidic acid. | 10-16-2014 |
| 20150126478 | ACCELERATED PROGRESSION RELAPSE TEST - An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MK167, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures. | 05-07-2015 |
| 20150290226 | NOVEL LYOPHILIZED COMPOSITIONS OF CYCLOPHOSPHAMIDE - The present invention relates to the process for producing novel lyophilized compositions of Cyclophosphamide, wherein the process does not need rehydration step. The compositions of the present invention have greater stability and uniformity. | 10-15-2015 |
| 20150315220 | NOVEL DERIVATIVES OF OXAZAPHOSPHORINES THAT ARE PRE-ACTIVATED, USE AND METHOD OF PREPARATION - The present invention relates to novel derivatives of oxazaphosphorines that are pre-activated, to the methods for preparing same, to the pharmaceutical compositions containing same and to the therapeutic use thereof, in particular for treating cancer. | 11-05-2015 |
| 20150320774 | FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE - Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing composition of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C. | 11-12-2015 |
| 20150320775 | FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE - Cyclophosphamide containing compositions preferably in the form of solutions having extended stability are disclosed. The compositions contain cyclophosphamide, ethanol and an ethanol soluble acidifying agent such as citric acid. Ready to dilute or ready to use cyclophosphamide containing composition of the invention maintain high levels cyclophosphamide content after about 18 or 24 months at a temperature of about 5° C. | 11-12-2015 |
| 20150376216 | SUGAR-ANALOG PHOSPHORUS-CONTAINING HETEROCYCLES HAVING AN ANTI-METASTATIC ACTIVITY - The use of compounds of formula (1) as defined in the description, for reducing or preventing the onset of metastases in a patient suffering from cancer. Pharmaceutical compositions for using in human or veterinary medicine, including at least one compound of formula (1) are also described. | 12-31-2015 |
| 20160068914 | PLASMA CELL DISORDERS - The invention relates to novel biological markers for plasma cell disorders, such as multiple myeloma, and in particular to the use of microRNAs as diagnostic and prognostic markers in assays for detecting such disorders. The invention also relates to methods of determining the efficacy of treating a plasma cell disorder with a therapeutic agent, and kits for carrying 5 out the assays and methods. The assays are qualitative and/or quantitative, and are adaptable to large-scale screening and clinical trials. | 03-10-2016 |
| 20160378934 | ACCELERATED PROGRESSION RELAPSE TEST - An Accelerated Progression Relapse Test (APRT) and method is provided for use in the prognosis of a patient having an ER+ breast cancer. The APRT provides a determination of when a patient in a particular diseased state is likely to benefit from further disease treatment, or does not have a high probability of benefit with additional treatment. Four genetic probes are disclosed that target the MK167, CDC6 and SPAG5 gene and gene products. The ER+ breast cancer patient population is stratified into two groups, with the low gene expression group identifying the patient/patient group that is less likely to benefit from additional treatment measures, and a high gene expression group identifying the patient group that is more likely to benefit from additional treatment measures. | 12-29-2016 |
| 20170232015 | FORMULATIONS OF CYCLOPHOSPHAMIDE LIQUID CONCENTRATE | 08-17-2017 |
| 514111000 | Polycyclo ring system having the phosphorus containing ring as one of the cyclos | 2 |
| 20130096092 | THIOETHER PRODRUG COMPOSITIONS AS ANTI-HIV AND ANTI-RETROVIRAL AGENTS - Disclosed are inhibitors of retroviral growth of formula (I), that are useful in treatment of retroviral infections such as HIV. Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound or salt of the invention, a method for inactivating a virus, a method for dissociating a metal ion from a zinc finger-containing protein, and a method for inhibiting the transmission of a virus. | 04-18-2013 |
| 20160060197 | PHENOL DERIVATIVE AND PREPARATION METHOD AND USE IN MEDICINE THEREOF - The present invention relates to a phenol derivative and the preparation method and use in medicine thereof, and particular to a phenol derivative represented by general formula (A) or a stereoisomer, a solvate, a metabolite, a prodrug, a pharmaceutically acceptable salt or a cocrystal thereof, a preparation method thereof, a pharmaceutical composition comprising the same, and use of the compound or composition of the present invention in the field of the central nervous system; wherein the definitions of substituents in general formula (A) are the same as those in the Description. | 03-03-2016 |
